Back to search

National and Kapodistrian University of Athens

Η συμβολή του Infliximab (anti-TNFa) ως αντιουλωτικού παράγοντα στην επέμβαση του γλαυκώματος

Abstract

dc:description

Glaucoma filtration surgery induces tissue injury that stimulates the body to commence a complex series of precisely controlled events, which define the process of wound healing. TNF-a plays a vital role throughout this process, as it participates in clotting, inflammation and apoptosis. Infliximab is a chimeric monoclonal antibody that binds to both soluble and transmembrane proinflammatory cytokine TNF-α. We hypothesized that blocking TNF-a with Infliximab would reduce both inflammation and fibrosis post glaucoma filtration surgery and consequently enhance bleb survival. Our results have shown that trabeculectomies in the Infliximab group failed faster and displayed more scarring, compared to the control and MMC group. Vascularity though was less significant in the Infliximab group compared to the control group. This outcome, suggests that the Infliximab doses used in this pilot study, resulted in a subconjunctival TNF-a concentration, which probably acted as a stimulator to fibroblasts, but not for angiogenesis. In order to reproduce the current golden standard technique of MMC application, Infliximab was administered under the conjunctiva through soaked sponges, in a pre-determined filtration area and then irrigated with saline. It is unknown whether the same concentrations of Infliximab would have produced different clinical outcomes, had it not been washed out or had it been administered through a subconjunctival injection at the beginning of surgery. Our data also showed a statistically significant decrease in cellular density in the MMC group, compared to the other groups. This echoes multiple studies demonstrating that MMC causes wide spread cell death and apoptosis. No differences were found in cellular density and scarring amongst various concentrations of Infliximab. This could imply that for topical Infliximab administration, larger concentration variances would be required to produce a detectable clinical difference. In conclusion, our outcomes indicate that Infliximab, when administered subconjunctivally during experimental glaucoma filtration surgery, in concentrations ranging from 10-50 mg/ml, accelerates scarring and bleb failure. The ideal anti-fibrotic agent, which will modulate wound healing, whilst minimizing side effects is yet to be defined.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Nikita, Eleni
  • Νικήτα, Ελένη

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44282

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Nikita, Eleni; Νικήτα, Ελένη. Η συμβολή του Infliximab (anti-TNFa) ως αντιουλωτικού παράγοντα στην επέμβαση του γλαυκώματος. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/44282